Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial
Open Access
- 2 May 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (5) , 604
Abstract
Physiologically based pharmacokinetic (PBPK) modelling for biologics, such as monoclonal antibodies and therapeutic proteins, involves capturing complex processes, including target-mediated drug disposition (TMDD), FcRn-mediated recycling, and tissue-specific distribution. The Simcyp Designer Biologics PBPK Platform Model offers an intuitive and efficient platform for constructing mechanistic PBPK models with pre-defined templates and automated model assembly, reducing manual input and improving reproducibility. This tutorial provides a step-by-step guide to using the platform, highlighting features such as cross-species scaling, population variability simulations, and flexibility for model customization. Practical case studies demonstrate the platform’s capability to streamline workflows, enabling rapid, mechanistic model development to address key questions in biologics drug development. By automating critical processes, this tool enhances decision-making in translational research, optimizing the modelling and simulation of large molecules across discovery and clinical stages.Keywords
This publication has 43 references indexed in Scilit:
- QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generationCPT: Pharmacometrics & Systems Pharmacology, 2023
- Predicting the Onset of Nonlinear PharmacokineticsCPT: Pharmacometrics & Systems Pharmacology, 2018
- A Tutorial on Target-Mediated Drug Disposition (TMDD) ModelsCPT: Pharmacometrics & Systems Pharmacology, 2015
- Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theoryJournal of Pharmacokinetics and Pharmacodynamics, 2015
- Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspectiveClinical Pharmacology & Therapeutics, 2015
- Applications of minimal physiologically-based pharmacokinetic modelsJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and humanJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Silencing disease genes in the laboratory and the clinicThe Journal of Pathology, 2011
- Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug developmentEuropean Journal of Drug Metabolism and Pharmacokinetics, 2000
- Half-life of the maternal IgG1 allotype in infantsJournal of Clinical Immunology, 1993